Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
Fiche publication
Date publication
février 2023
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENGRINE-LEFEVRE Leila, Dr GAVOILLE Céline
Tous les auteurs :
Bourien H, Lefevre LB, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Gavoille L, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Tixidre CG, Coeffic D, Morvan A, Collard O, DE LA Motte Rouge T
Lien Pubmed
Résumé
Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following the results of the Study 19. We present the results of a national real-world study on the effectiveness of olaparib in relapsed BRCA-mutated EOC patients.
Mots clés
BRCA, BRCA mutation, Ovarian cancer, PARPi, olaparib, platinum, relapsed ovarian cancer, routine clinical practice
Référence
Anticancer Res. 2023 02;43(2):653-662